SalioGen Therapeutics is a biotechnology company developing Gene CodingTM, a new category of genetic medicine.
SalioGen's mission is to transform the treatment paradigm for patients with inherited disorders by developing durable, broadly applicable, life-altering therapies grounded in innovative and rigorous science.
SalioGen was founded in 2020 by Joseph Higgins. The company is headquartered in Cambridge, Massachusetts.
SalioGen has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration TechnologyTM (EDITTM) platform.
SalioGen's Gene Coding approach is guided by their Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes they call Saliogase.
SalioGen is backed by GordonMD Global Investments, PBM Capital, EPIQ Capital Group, Fidelity Management & Research Company, T. Rowe Price Associates, D1 Capital Partners, SymBiosis, and others. The company closed a $115M Series B round on Jan 05, 2022. This brings SalioGen's total funding to $135M to date.